2月24日 - ** 药物开发商 Vir Biotechnology VIR.O股价盘前上涨 65.2%，报 12.28 美元
** 该公司公布第四季度营收6410万美元，超过分析师预计的2310万美元；公布的第四季度每股亏损31美分，而共识亏损为49美分--数据由LSEG编译。
** 公司强调了与 Norgine 签订的 (link) 协议，以及因重组措施而降低的研发费用。
** 该公司还计划与日本安斯泰来斯公司 (link) 4503.T 合作开发并商业化其前列腺癌实验药物。
** 截至上次收盘，VIR 的股价在 2025 年下跌 17.8% 后，今年累计上涨 23.2%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.